摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-((tetrahydro-2H-pyran-2-yl)oxy)benzo[d]isoxazol-3-amine | 1448675-04-4

中文名称
——
中文别名
——
英文名称
6-((tetrahydro-2H-pyran-2-yl)oxy)benzo[d]isoxazol-3-amine
英文别名
6-[(Tetrahydro-2H-pyran-2-yl)oxy]-1,2-benzisoxazol-3-amine;6-(oxan-2-yloxy)-1,2-benzoxazol-3-amine
6-((tetrahydro-2H-pyran-2-yl)oxy)benzo[d]isoxazol-3-amine化学式
CAS
1448675-04-4
化学式
C12H14N2O3
mdl
——
分子量
234.255
InChiKey
SPAPEMGSMUESHB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    445.2±45.0 °C(Predicted)
  • 密度:
    1.305±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    70.5
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-((tetrahydro-2H-pyran-2-yl)oxy)benzo[d]isoxazol-3-amine盐酸 、 5%-palladium/activated carbon 、 氢气potassium carbonate 作用下, 以 甲醇乙腈 为溶剂, 反应 8.0h, 生成 ethyl 3-(4-carbamimidoyl-3-hydroxyphenoxy)-2-hydroxypropanoate
    参考文献:
    名称:
    [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
    [FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS
    摘要:
    本发明涉及式(I)的新型β-内酰胺化合物,它们的制备和使用。特别是,本发明涉及作为抗菌剂有用的新型β-内酰胺化合物,即取代脒的单巴坦衍生物及其制备方法。
    公开号:
    WO2013110643A1
  • 作为产物:
    参考文献:
    名称:
    [EN] AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
    [FR] COMPOSÉS DE BÊTA-LACTAME À SUBSTITUTION AMIDINE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS
    摘要:
    本发明涉及式(I)的新型β-内酰胺化合物,它们的制备和使用。特别是,本发明涉及作为抗菌剂有用的新型β-内酰胺化合物,即取代脒的单巴坦衍生物及其制备方法。
    公开号:
    WO2013110643A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING<br/>[FR] THIOPHÈNES CONDENSÉS SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS DE STING
    申请人:CTXT PTY LTD
    公开号:WO2019219820A1
    公开(公告)日:2019-11-21
    A compound of formula (I), wherein: R1 is selected from (i) H, (ii) C3-6cycloalkyl, (iii) C3-7heterocyclyl optionally substituted with a group selected from: methyl and ester, and (iv) linear or branched C1-4alkyl optionally substituted with a group selected from: alkoxy, amino, amido, acylamido, acyloxy, alkyl carboxyl ester, alkyl carbamoyl, alkyl carbamoyl ester, phenyl, phosphonate ester, C3-7heterocyclyl optionally substituted with a group selected from methyl and oxo, and a naturally occurring amino acid, optionally N-substituted with a group selected from methyl, acetyl and boc; A1 is CRA or N; A2 is CRB or N; A3 is CRC or N; A4 is CRD or N; where no more than two of A1, A2, A3, and A4 may be N; one or two of RA, RB, RC, and RD, (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and CH2NMe2; the remainder of RA, RB, RC, and RD, (if present) are H; Y is O, NH or CH2; RY is selected from: (RYA) and (RYB).
    化合物的化学式(I),其中:R1选自(i)H,(ii)C3-6环烷基,(iii)C3-7杂环烷基,可选择地取代为:甲基和酯,以及(iv)线性或支链C1-4烷基,可选择地取代为:烷氧基,氨基,酰胺基,酰氧基,烷基羧酯,烷基氨基,烷基氨基酯,苯基,磷酸酯,C3-7杂环烷基,可选择地取代为甲基和氧代基,以及一种天然氨基酸,可选择地N-取代为:甲基,乙酰基和boc;A1为CRA或N;A2为CRB或N;A3为CRC或N;A4为CRD或N;其中A1,A2,A3和A4中最多有两个可以是N;RA,RB,RC和RD中的一个或两个(如果存在)选自H,F,Cl,Br,Me,CF3,环丙基,氰基,OMe,OEt,CH2OH,CH2OMe和CH2NMe2;RA,RB,RC和RD的其余部分(如果存在)为H;Y为O,NH或CH2;RY选自:(RYA)和(RYB)。
  • [EN] COMPOUNDS<br/>[FR] COMPOSÉS
    申请人:CTXT PTY LTD
    公开号:WO2019243491A1
    公开(公告)日:2019-12-26
    A compound of formula (I), or a pharmaceutical salt thereof.
    式(I)的化合物,或其药用盐。
  • AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
    申请人:AiCuris GmbH & Co. KG
    公开号:US20150045340A1
    公开(公告)日:2015-02-12
    The present invention relates to novel β-lactam compounds, their preparation and use. In particular, this invention relates to novel β-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.
    本发明涉及新型β-内酰胺化合物、它们的制备和用途。特别地,本发明涉及新型β-内酰胺化合物,其是取代了氨基甲酰基的单环内酰胺衍生物,可用作抗微生物剂,以及它们的制备。
  • Exploration of the linkage elements of porcupine antagonists led to potent Wnt signaling pathway inhibitors
    作者:Yan Dong、Kehuang Li、Zhixiang Xu、Haikuo Ma、Jiyue Zheng、Zhilin Hu、Sudan He、Yiyuan Wu、Zhijian Sun、Lusong Luo、Jiajun Li、Hongjian Zhang、Xiaohu Zhang
    DOI:10.1016/j.bmc.2015.09.048
    日期:2015.11
    The Wnt signaling pathway is a pivotal developmental pathway. It operates through control of cellular functions such as proliferation, differentiation, migration and polarity. Aberrant Wnt signaling has been implicated in the formation and metastasis of tumors. Porcupine is a component of the Wnt signaling pathway. It is a member of the membrane-bound O-acyltransferase family of proteins. Porcupine catalyzes the palmitoylation of Wnt proteins, a process which is essential to their secretion and activity. Here we report a novel series of compounds obtained by a scaffold hybridization strategy from two known porcupine inhibitor classes. The leading compound 62 demonstrated subnanomolar (IC50 0.11 nM) inhibition of Wnt signaling in a paracrine cellular reporter gene assay. Compound 62 also potently inhibited Wnt secretion into culture medium, an indication of direct inhibition of the porcupine protein. Furthermore, compound 62 showed excellent chemical, plasma and liver microsomal stabilities. Collectively, these results strongly support further optimization of this novel scaffold to develop better Wnt pathway inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.
  • AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
    申请人:AiCuris GmbH & Co. KG
    公开号:EP2806873A1
    公开(公告)日:2014-12-03
查看更多

同类化合物

苯并异恶唑Hsp90抑制剂 苯并[d]异噁唑-7-醇 苯并[d]异噁唑-5-胺 苯并[d]异噁唑-5-磺酰氯 苯并[D]异恶唑-3-甲酸 苯[D]异恶唑-3-醇 羟基伊洛哌酮 甲基6-氨基-1,2-苯并恶唑-3-羧酸酯 环己酮,2,3-二甲基-6-(1-甲基乙基)-,[2R-(2α,3ba,6ba)]-(9CI) 帕潘立酮杂质1 奈氟齐特 四氢-4-[[[4-[[[4-[[(3R)-四氢-3-呋喃基]氧基]-1,2-苯并恶唑-3-基]氧基]甲基]-1-哌啶基]甲基]-2H-吡喃-4-醇 唑尼酰胺-d4 唑尼沙胺钠 唑尼沙胺13C2-15N 唑尼沙胺 呋喃并[3,4:3,4]环丁二烯并[1,2:3,4]环丁二烯并[1,2-d]异噻唑(9CI) 呋喃并[3,4-f][1,2]苯并恶唑 呋喃并[3,4-e][1,2]苯并恶唑 呋喃并[3,2-g][1,2]苯并恶唑 呋喃并[3,2-f]-1,2-苯并异恶唑 呋喃并[2,3-f][1,2]苯并恶唑 呋喃并[2,3-e][1,2]苯并恶唑 叔-丁基(6-溴苯并[D]异噻唑-3-基)氨基甲酯 化合物 T29498 佐尼氯唑 伊潘立酮(R)-羟基杂质 alpha-甲基-3-苯基-1,2-苯并异恶唑-7-乙酸 [1,2]恶唑并[5,4-f][1,2]苯并恶唑 [1,2]恶唑并[5,4-e][2,1,3]苯并恶二唑 [1,1'-联苯基]-3-醇,2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)- [(3-氨基-1,2-苯并异恶唑-5-基)甲基]氨基甲酸叔丁酯 N,N-二甲基唑尼沙胺杂质 N-甲氧基-N-甲基苯并[d]异恶唑-3-甲酰胺 N-甲基唑尼沙胺 N-乙基苯异恶唑酮四氟硼酸盐 N-[(1,2-苯并恶唑-3-基甲基)磺酰基]乙酰胺 N-(苯并[D]异恶唑-3-基氧基-二甲基氨基-磷酰)-N-甲基-甲胺 N-(6-己酸)唑尼沙胺 7-硝基-1,2-苯并恶唑 7-甲氧基-3-甲基-1,2-苯并恶唑 7-甲基苯并[d]异恶唑-3-醇 7-溴苯并[d]异噁唑 7-溴苯并[D]异恶唑-3(2H)-酮 7-溴-3-氯苯并[D]异恶唑 7-溴-1,2-苯并恶唑-3-胺 7-氯-苯并[d]异恶唑 7-氟苯并[d]异噁唑-3-胺 7-氟-苯并[d]异噁唑-3-醇 6-苯基苯并[d]异噁唑-3-胺